Impax Laboratories, Inc. (NASDAQ:IPXL) reported Q2 2017 earnings this Morning, coming in at $0.18 per share, beating Wall Street’s estimates of $0.14 per Share. Revenue for the quarter came in at $202.08 million beating analyst estimates of $195.62 million
Analyst Coverage For Impax Laboratories, Inc. (NASDAQ:IPXL)
These are 1 Sell Rating, 9 Hold Ratings, 4 Buy Ratings .
The current consensus rating for Impax Laboratories, Inc. (NASDAQ:IPXL) is Hold (Score: 2.21) with a consensus target price of $19.64 , a potential (30.09% upside)Recent Insider Trading for Impax Laboratories, Inc. (NASDAQ:IPXL)
- On 5/31/2017 Michael Nestor, Insider, sold 1,130 with an average share price of $15.00 per share and the total transaction amounting to $16,950.00.
- On 5/17/2017 Michael Nestor, Insider, sold 857 with an average share price of $16.48 per share and the total transaction amounting to $14,123.36.
- On 5/12/2017 Michael Nestor, Insider, sold 700 with an average share price of $17.11 per share and the total transaction amounting to $11,977.00.
- On 8/15/2016 Leslie Z Benet, Director, sold 10,092 with an average share price of $22.81 per share and the total transaction amounting to $230,198.52.
- On 9/11/2015 Mark A Schlossberg, SVP, sold 7,457 with an average share price of $43.30 per share and the total transaction amounting to $322,888.10.
- On 9/10/2015 Michael Nestor, Insider, sold 5,000 with an average share price of $43.56 per share and the total transaction amounting to $217,800.00.
Recent Trading for Impax Laboratories, Inc. (NASDAQ:IPXL) Shares of Impax Laboratories, Inc. closed the previous trading session at 16.65 up +1.55 10.26% with 3,022,930 shares trading hands.